Ozempic vs Zepbound Cost Comparison 2026: Real Prices Side-by-Side

Ozempic and Zepbound get compared constantly, and for good reason — they're the two GLP-1 medications most patients actually consider. But they're not really apples-to-apples: Ozempic is FDA-approved for type 2 diabetes and prescribed off-label for weight loss, while Zepbound is FDA-approved specifically for chronic weight management. The cost difference between them depends heavily on how you're paying and which indication your prescription is for. Here's the full picture for 2026.

Head-to-head: every price path

The self-pay pricing reality

Both Novo Nordisk (Ozempic) and Eli Lilly (Zepbound) now operate direct-to-patient pharmacies that bypass traditional insurance entirely. This is where most uninsured or underinsured patients get the real price.

Ozempic through NovoCare Pharmacy

NovoCare Pharmacy is Novo Nordisk's direct-to-patient channel. For new self-pay patients, Novo Nordisk offers a limited-time $199/month price on the 0.25mg and 0.5mg starter doses for the first two months, with the offer valid through early 2026. After that intro period, the standard self-pay price is $349/month for 0.25mg, 0.5mg, or 1mg, and $499/month for the 2mg maintenance dose. There's free home delivery or pickup at over 70,000 pharmacy locations, and the pricing also applies through partners like Costco, GoodRx, WeightWatchers, Ro, and LifeMD.

Zepbound through LillyDirect

LillyDirect is Eli Lilly's equivalent self-pay platform. The starting 2.5mg vial is $299/month, 5mg is $399/month, and the higher doses (7.5mg through 15mg) are $449/month through the Zepbound Self Pay Journey Program — but only if you refill within 45 days of your previous delivery. Miss that 45-day window and you'll pay the standard price: $499 for 7.5mg, $699 for 10mg, $849 for 12.5mg, or $1,049 for 15mg at the vial tier, or up to $699/month on the KwikPen. Beginning February 23, 2026, the Self Pay Journey Program also applies to the KwikPen (single-patient-use) at $449/month for 7.5–15mg doses.

Side-by-side self-pay cost by dose

On pure self-pay cost, Ozempic beats Zepbound at almost every dose tier. But this comparison has an asterisk: Ozempic is FDA-approved for type 2 diabetes, not obesity. Using it for weight loss is off-label. If your goal is weight loss specifically, the on-label option from Novo Nordisk is Wegovy (same active ingredient, different branding, slightly different dose schedule) at similar pricing.

With insurance: the coverage gap that matters

When you have commercial insurance with GLP-1 coverage, both Ozempic and Zepbound typically land at $25/month with manufacturer savings cards. The catch: coverage itself is wildly asymmetric between the two drugs.

Because Ozempic is approved for type 2 diabetes, it's covered on virtually every commercial drug formulary in the US for diabetic patients. Zepbound, approved for obesity and obstructive sleep apnea, faces a much harder coverage fight. Obesity coverage is excluded entirely from many employer plans, and prior authorization requirements for Zepbound are significantly stricter.

Coverage odds in 2026

Effectiveness: does the price difference buy better results?

This matters because paying more for Zepbound only makes sense if it delivers proportionally more weight loss. The clinical trial data has a clear answer:

• Ozempic/Wegovy (semaglutide): The STEP trials showed average weight loss of approximately 15% of body weight over 68 weeks for semaglutide users combined with diet and exercise.
• Zepbound (tirzepatide): The SURMOUNT trials showed average weight loss of approximately 20–21% of body weight over 72 weeks — and the head-to-head SURMOUNT-5 trial directly compared tirzepatide against semaglutide and found tirzepatide delivered significantly greater weight loss.

So yes, Zepbound does produce more weight loss on average. The question is whether a ~5 percentage point efficacy advantage (roughly 10–15 additional pounds for a 200-pound starting weight) justifies a ~$1,300/year premium on self-pay. For patients with 50+ pounds to lose or who haven't responded to semaglutide, it often does. For patients earlier in their journey or with less weight to lose, Ozempic/Wegovy may be more than enough.

The compounded alternative — and why it matters for this comparison

There's a third pathway that changes the math: compounded versions of semaglutide (the active ingredient in Ozempic) and tirzepatide (the active ingredient in Zepbound). Compounded medications are prepared by licensed pharmacies using the same active ingredients but are not FDA-approved as finished products. In 2026, compounded semaglutide runs roughly $146–$299/month and compounded tirzepatide runs roughly $258–$399/month across major telehealth providers.

This means the compounded alternative to Ozempic is often cheaper than Ozempic NovoCare self-pay, and the compounded alternative to Zepbound is often cheaper than LillyDirect self-pay. The tradeoff is regulatory: compounded medications haven't been evaluated by the FDA for safety, effectiveness, or quality, and the regulatory environment around compounded GLP-1s has tightened since the shortages ended. Patients on compounded plans should know this risk upfront and have a backup plan in mind.

Which one is cheaper for you, specifically?

The honest answer depends on four variables. Here's how to figure it out quickly:

1. Do you have type 2 diabetes or prediabetes? If yes, Ozempic with commercial insurance is almost certainly the cheapest path at $25/month. Zepbound isn't FDA-approved for diabetes.
2. Is your primary goal weight loss? If yes and you have insurance, check whether your plan covers Zepbound for obesity (many plans have started covering it in 2025–2026). If covered, it's $25/month.
3. No insurance, or insurance doesn't cover either? Ozempic through NovoCare self-pay is cheaper at every dose except the 15mg Zepbound vial ($449 vs. Ozempic 2mg at $499). But Zepbound delivers more weight loss on average.
4. Absolute lowest cost matters most? Compounded semaglutide from a licensed telehealth provider can drop monthly cost to under $200 — cheaper than either brand-name option — but with the regulatory asterisk noted above.

Cost projections over 12 months

What's changing in 2026 and 2027

The pricing landscape for both drugs is in active motion. Two shifts worth watching:

List price cuts coming January 2027. Novo Nordisk announced in February 2026 that the list price for Wegovy, Ozempic, and Rybelsus will drop to roughly $675/month starting January 1, 2027 — about a 50% reduction. This is designed to help patients on high-deductible plans or with coinsurance-based cost sharing. It doesn't directly change NovoCare self-pay pricing, but it reduces the gap between list and cash.

TrumpRx and government negotiation. The TrumpRx.gov program launched in February 2026 offers Zepbound at roughly $350/month without insurance as part of a federal direct-to-consumer pricing agreement. Medicare's GLP-1 Bridge at $50/month copays starts in July 2026 for qualifying beneficiaries. Expect continued downward pressure on cash prices through the year.

The bottom line

For most patients paying cash, Ozempic is cheaper than Zepbound at every dose tier except the very top, with NovoCare self-pay running roughly $1,300 less per year than LillyDirect. For patients with insurance that covers either drug, the copay is identical at $25/month and the question collapses to which medication is medically right. For patients seeking maximum efficacy and willing to pay for it, Zepbound's 20–21% weight loss vs. semaglutide's 15% is a real and reproducible difference.

Most patients end up in one of three buckets: insurance-covered Ozempic for diabetes (cheapest overall), compounded semaglutide through telehealth (cheapest cash-pay), or Zepbound self-pay for patients who specifically want on-label FDA-approved obesity treatment and are willing to pay the premium. Model your own 12-month cost across all four pathways with our True Monthly Cost Calculator, or see live prices from every major provider on our main comparison page.